6.44
0.94%
0.06
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BMEA Giù?
Forum
Previsione
Precedente Chiudi:
$6.38
Aprire:
$6.36
Volume 24 ore:
491.19K
Relative Volume:
0.61
Capitalizzazione di mercato:
$233.38M
Reddito:
-
Utile/perdita netta:
$-144.01M
Rapporto P/E:
-1.9398
EPS:
-3.32
Flusso di cassa netto:
$-113.02M
1 W Prestazione:
-1.38%
1M Prestazione:
-43.85%
6M Prestazione:
-44.00%
1 anno Prestazione:
-35.79%
Biomea Fusion Inc Stock (BMEA) Company Profile
Nome
Biomea Fusion Inc
Settore
Industria
Telefono
(650) 980-9099
Indirizzo
900 MIDDLEFIELD ROAD, REDWOOD CITY
Confronta BMEA con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
BMEA | 6.44 | 233.38M | 0 | -144.01M | -113.02M | -3.32 |
VRTX | 450.97 | 116.14B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 738.00 | 81.10B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 605.92 | 36.23B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 113.13 | 27.12B | 3.30B | -501.07M | 1.03B | 11.54 |
Biomea Fusion Inc Stock (BMEA) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-10-09 | Iniziato | Edward Jones | Buy |
2024-09-27 | Aggiornamento | Rodman & Renshaw | Neutral → Buy |
2024-09-27 | Aggiornamento | Truist | Hold → Buy |
2024-08-29 | Iniziato | CapitalOne | Overweight |
2024-06-11 | Downgrade | Truist | Buy → Hold |
2024-06-07 | Downgrade | Barclays | Overweight → Equal Weight |
2024-04-02 | Downgrade | JP Morgan | Overweight → Neutral |
2024-02-06 | Iniziato | Truist | Buy |
2023-07-27 | Iniziato | Scotiabank | Sector Outperform |
2023-06-26 | Downgrade | Jefferies | Buy → Hold |
2023-05-12 | Iniziato | Barclays | Overweight |
2023-03-29 | Reiterato | Oppenheimer | Outperform |
2023-03-28 | Reiterato | H.C. Wainwright | Buy |
2023-02-24 | Iniziato | Citigroup | Buy |
2022-06-02 | Ripresa | H.C. Wainwright | Buy |
2022-01-12 | Iniziato | H.C. Wainwright | Buy |
2021-12-17 | Iniziato | Oppenheimer | Outperform |
2021-05-11 | Iniziato | JP Morgan | Overweight |
2021-05-11 | Iniziato | Jefferies | Buy |
2021-05-11 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Biomea Fusion Inc Borsa (BMEA) Ultime notizie
HC Wainwright Reaffirms Buy Rating for Biomea Fusion (NASDAQ:BMEA) - Defense World
Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
HC Wainwright Reiterates Buy Rating for Biomea Fusion (NASDAQ:BMEA) - MarketBeat
Late-Breaker Oral Presentation Showing New Analysis from the Escalation Portion of COVALENT-111 Presented at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024) - The Manila Times
Late-Breaker Oral Presentation Showing New Analysis from - GlobeNewswire
Biomea Fusion's Diabetes Drug Shows 1.23% HbA1c Drop in Key Patient Group | BMEA Stock News - StockTitan
(BMEA) Investment Report - Stock Traders Daily
We're A Little Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Rate - Yahoo Finance
How To Trade (BMEA) - Stock Traders Daily
Biomea Fusion, Inc. Reveals Preclinical Data on Icovamenib and BMF-650 in Recent SEC Filing - Defense World
Biomea Fusion's SWOT analysis: clinical hold clouds diabetes drug stock outlook - Investing.com India
Biomea Fusion FY2024 EPS Estimate Raised by HC Wainwright - Defense World
HC Wainwright Forecasts Increased Earnings for Biomea Fusion - MarketBeat
Biomea Fusion (NASDAQ:BMEA) Stock Price Expected to Rise, Piper Sandler Analyst Says - Defense World
Biomea Fusion’s (BMEA) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
BMEABiomea Fusion, Inc. Latest Stock News & Market Updates - StockTitan
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Biomea Fusion stock PT raised by Piper Sandler, citing pipeline potential - Investing.com Australia
HC Wainwright Reiterates "Buy" Rating for Biomea Fusion (NASDAQ:BMEA) - MarketBeat
Biomea Fusion Unveils Promising Diabetes Treatment Innovations - TipRanks
Biomea Fusion Reports Q3 2024 Financial Results - MSN
Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate - GlobeNewswire
Barclays Forecasts Strong Price Appreciation for Biomea Fusion (NASDAQ:BMEA) Stock - MarketBeat
Biomea Awaits 2 Data Readouts Of Diabetes StudiesCan The Stock Get Its Mojo Back? - RTTNews
Biomea Fusion (NASDAQ:BMEA) Announces Earnings Results - MarketBeat
Biomea Fusion price target raised to $11 from $9 at Barclays - TipRanks
Biomea Fusion reports Q3 EPS (91c), consensus (95c) - TipRanks
Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights - The Manila Times
Biomea Fusion options imply 6.1% move in share price post-earnings - TipRanks
Biomea Fusion, Inc. (NASDAQ:BMEA) Given Average Rating of "Buy" by Brokerages - MarketBeat
Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Consensus Rating of “Buy” from Brokerages - Defense World
(BMEA) Technical Data - Stock Traders Daily
Biomea Fusion shares maintain Buy rating from H.C. Wainwright By Investing.com - Investing.com Australia
Biomea Fusion's (BMEA) Buy Rating Reiterated at HC Wainwright - MarketBeat
Biomea Fusion shares maintain Buy rating from H.C. Wainwright - Investing.com
Exchange Traded Concepts LLC Acquires 8,079 Shares of Biomea Fusion, Inc. (NASDAQ:BMEA) - Defense World
Biomea Fusion's icovamenib gets global and US naming approval - Investing.com India
Biomea Fusion's icovamenib gets global and US naming approval By Investing.com - Investing.com South Africa
Biomea Fusion announces approval of ‘icovamenib’ as INN for BMF-219 - TipRanks
Biomea Fusion Announces Approval of 'icovamenib” as International Nonproprietary Name for BMF-219 - The Manila Times
Biomea Fusion Announces Approval of “icovamenib” as International Nonproprietary Name for BMF-219 - GlobeNewswire
Biomea Fusion (NASDAQ:BMEA) & Acrivon Therapeutics (NASDAQ:ACRV) Financial Survey - Defense World
(BMEA) Investment Analysis and Advice - Stock Traders Daily
Griffin Asset Management Inc. Purchases 57,180 Shares of Biomea Fusion, Inc. (NASDAQ:BMEA) - MarketBeat
Biomea Fusion to Host Conference Call and Webcast on Wednesday, October 30th at 4:30 pm ET to Announce Our Lead Clinical Candidate, BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist and Preclinical Data Combining BMF-21 - The Manila Times
Biomea Fusion Inc Azioni (BMEA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):